Literature DB >> 8788417

Carbamazepine exerts anti-inflammatory effects in the rat.

M Bianchi1, G Rossoni, P Sacerdote, A E Panerai, F Berti.   

Abstract

In a first set of experiments, we evaluated the effects of different doses (5.0, 10, 20 and 40 mg/kg p.o.) of carbamazepine on nociceptive thresholds to thermal and mechanical stimuli, and on paw inflammatory hyperalgesia induced by the injection of brewer's yeast. Moreover, we studied the effect of carbamazepine on paw inflammatory edema by plethysmometry. Carbamazepine did not modify nociceptive latencies, but dose dependently reduced the hyperalgesia and the edema induced by the brewer's yeast injection in the rat hindpaw. In a second set of experiments, we studied the effects induced by the same doses of the drug on subcutaneous carrageenin-induced inflammation. Carbamazepine dose dependently reduced the inflammatory exudate, the prostaglandin E2-like activity in the exudate, and the substance P concentrations in the exudate. Our results demonstrate that carbamazepine is able to inhibit the development of different types of inflammation in the rat.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8788417     DOI: 10.1016/0014-2999(95)00516-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Population-level evidence for an autoimmune etiology of epilepsy.

Authors:  Mei-Sing Ong; Isaac S Kohane; Tianxi Cai; Mark P Gorman; Kenneth D Mandl
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

Review 2.  Treating Immune-Related Epilepsy.

Authors:  Sonal Bhatia; Sarah E Schmitt
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-14       Impact factor: 5.081

3.  Antinociceptive action of carbamazepine on thermal hypersensitive pain at spinal level in a rat model of adjuvant-induced chronic inflammation.

Authors:  Tatsushige Iwamoto; Yoshihiro Takasugi; Hideaki Higashino; Hiroyuki Ito; Yoshihisa Koga; Shinichi Nakao
Journal:  J Anesth       Date:  2010-11-27       Impact factor: 2.078

4.  Antiepileptic drug therapy in patients with autoimmune epilepsy.

Authors:  Anteneh M Feyissa; A Sebastian López Chiriboga; Jeffrey W Britton
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-05-10

Review 5.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

Review 6.  Pharmacological Investigations in Glia Culture Model of Inflammation.

Authors:  Fatme Seval Ismail; Franco Corvace; Pedro M Faustmann; Timo Jendrik Faustmann
Journal:  Front Cell Neurosci       Date:  2021-12-16       Impact factor: 5.505

7.  Tricyclic antidepressants and selective serotonin reuptake inhibitors but not anticonvulsants ameliorate pain, anxiety, and depression symptoms in an animal model of central post-stroke pain.

Authors:  Bai Chuang Shyu; Alan Bh He; Ying H Yu; Andrew Chih Wei Huang
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

8.  Vitamin D3 and carbamazepine protect against Clostridioides difficile infection in mice by restoring macrophage lysosome acidification.

Authors:  Hung Chan; Qing Li; Xiansong Wang; Wing Yingzhi Liu; Wei Hu; Judeng Zeng; Chuan Xie; Thomas Ngai Yeung Kwong; Idy Hiu Ting Ho; Xiaodong Liu; Huarong Chen; Jun Yu; Ho Ko; Raphael Chiu Yeung Chan; Margaret Ip; Tony Gin; Alfred Sze Lok Cheng; Lin Zhang; Matthew Tak Vai Chan; Sunny Hei Wong; William Ka Kei Wu
Journal:  Autophagy       Date:  2022-01-06       Impact factor: 13.391

9.  Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1.

Authors:  Anteneh M Feyissa; Christopher Lamb; Sean J Pittock; Avi Gadoth; Andrew McKeon; Christopher J Klein; Jeffrey W Britton
Journal:  Epilepsia Open       Date:  2018-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.